Search for drugs:
Typing the drug name to query
IOBENGUANE I-131
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- The effect of AZEDRA on the QTc interval was evaluated in 74 patients with unresectable pheochromocytoma or paraganglioma. At the recommended therapeutic dosage, no large mean increases from baseline in the QTc interval (i.e., >20 ms) were detected.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- V09IX02 - iobenguane i-131
- V09IX - Other diagnostic radiopharmaceuticals for tumour detection
- V09I - TUMOUR DETECTION
- V09 - DIAGNOSTIC RADIOPHARMACEUTICALS
- V - VARIOUS
Active Ingredient:IOBENGUANE I-131
Active Ingredient UNII:Q461L7AK4R
Drugbank ID:DB06704
PubChem Compound:60860
CAS Number:80663-95-2
Dosage Form(s):injection, solution
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
NC(N)=NCC1=CC(I)=CC=C1
NC(N)=NCC1=CC(I)=CC=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.